Cargando…

Non-alcoholic Fatty Liver Disease and Steatohepatitis: Risk Factors and Pathophysiology

Non-alcoholic fatty liver disease (NAFLD) and its progressive subtype non-alcoholic steatohepatitis (NASH) are the most prevalent liver diseases, often leading to hepatocellular carcinoma (HCC). This review aims to describe the present knowledge of the risk factors responsible for the development of...

Descripción completa

Detalles Bibliográficos
Autor principal:	Akter, Sharmin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Iranian Association of Gastroerterology and Hepatology 2022
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9489315/ https://www.ncbi.nlm.nih.gov/pubmed/36619154 http://dx.doi.org/10.34172/mejdd.2022.270

Ejemplares similares

Role of MicroRNAs in Pathophysiology of Non-alcoholic Fatty Liver Disease and Non-alcoholic Steatohepatitis
por: Iravani, Farzaneh, et al.
Publicado: (2018)

Decoding the Pathophysiology of Non-alcoholic Fatty Liver Disease Progressing to Non-alcoholic Steatohepatitis: A Systematic Review
por: Yaqub, Sayma, et al.
Publicado: (2021)

Pathophysiology of Non Alcoholic Fatty Liver Disease
por: Petta, Salvatore, et al.
Publicado: (2016)

Immunological Mechanisms in the Pathophysiology of Non-Alcoholic Steatohepatitis
por: Vonghia, Luisa, et al.
Publicado: (2013)

Systematic review: the diagnosis and staging of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis
por: Dowman, J K, et al.
Publicado: (2011)

An Animal Model for the Juvenile Non-Alcoholic Fatty Liver Disease and Non-Alcoholic Steatohepatitis
por: Marin, Veronica, et al.
Publicado: (2016)

A Review Of Current And Upcoming Treatment Modalities In Non-Alcoholic Fatty Liver Disease And Non-Alcoholic Steatohepatitis
por: Ganguli, Surosree, et al.
Publicado: (2019)

Hepatokines and Non-Alcoholic Fatty Liver Disease: Linking Liver Pathophysiology to Metabolism
por: Kim, Tae Hyun, et al.
Publicado: (2021)

Epidemiology of non‐alcoholic fatty liver disease and non‐alcoholic steatohepatitis in Japan: A focused literature review
por: Eguchi, Yuichiro, et al.
Publicado: (2020)

Metabolomic analysis of human cirrhosis, hepatocellular carcinoma, non-alcoholic fatty liver disease and non-alcoholic steatohepatitis diseases
por: Safaei, Akram, et al.
Publicado: (2016)

Pathophysiological mechanisms of cardiovascular disorders in non-alcoholic fatty liver disease
por: Garbuzenko, Dmitry Victorovich
Publicado: (2022)

Detailed Molecular Mechanisms Involved in Drug-Induced Non-Alcoholic Fatty Liver Disease and Non-Alcoholic Steatohepatitis: An Update
por: Di Pasqua, Laura Giuseppina, et al.
Publicado: (2022)

Hypoxia-Inducible Factors as Key Players in the Pathogenesis of Non-alcoholic Fatty Liver Disease and Non-alcoholic Steatohepatitis
por: Holzner, Lorenz M. W., et al.
Publicado: (2021)

Pleiotropic Effects of Statins in the Light of Non-Alcoholic Fatty Liver Disease and Non-Alcoholic Steatohepatitis
por: Ahsan, Farah, et al.
Publicado: (2020)

Non-alcoholic fatty liver disease: pathophysiological concepts and treatment options
por: Grander, Christoph, et al.
Publicado: (2023)

Nonalcoholic Fatty Liver Disease/Non-Alcoholic Steatohepatitis in Childhood: Endocrine-Metabolic “Mal-Programming”
por: Manti, Sara, et al.
Publicado: (2014)

Imaging biomarkers for steatohepatitis and fibrosis detection in non-alcoholic fatty liver disease
por: Gallego-Durán, Rocío, et al.
Publicado: (2016)

Multiparametric MR Index for the Diagnosis of Non-Alcoholic Steatohepatitis in Patients with Non-Alcoholic Fatty Liver Disease
por: Kim, Jeong Woo, et al.
Publicado: (2020)

Pathophysiological Mechanisms in Non-Alcoholic Fatty Liver Disease: From Drivers to Targets
por: Santos-Laso, Alvaro, et al.
Publicado: (2021)

Role of microRNA in non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH): a comprehensive review
por: Kan Changez, Mah I, et al.
Publicado: (2023)

Non-alcoholic fatty liver disease (NAFLD)/non-alcoholic steatohepatitis (NASH)-related liver fibrosis: mechanisms, treatment and prevention
por: Tacke, Frank, et al.
Publicado: (2021)

Portal lymphadenopathy predicts non-alcoholic steatohepatitis and advanced fibrosis in non-alcoholic fatty liver disease
por: Daher, Saleh, et al.
Publicado: (2018)

Beneficial effect of omarigliptin on diabetic patients with non-alcoholic fatty liver disease/non-alcoholic steatohepatitis
por: Hattori, Sachiko, et al.
Publicado: (2021)

Hepcidin levels correlate to liver iron content, but not steatohepatitis, in non-alcoholic fatty liver disease
por: Marmur, Joel, et al.
Publicado: (2018)

Machine learning to predict progression of non‐alcoholic fatty liver to non‐alcoholic steatohepatitis or fibrosis
por: Ghandian, Sina, et al.
Publicado: (2022)

Long Non-Coding RNAs Involved in Progression of Non-Alcoholic Fatty Liver Disease to Steatohepatitis
por: Atanasovska, Biljana, et al.
Publicado: (2021)

Fibroblast growth factor signaling in non-alcoholic fatty liver disease and non-alcoholic steatohepatitis: Paving the way to hepatocellular carcinoma
por: Ocker, Matthias
Publicado: (2020)

Role of Extracellular Vesicles in the Pathophysiology, Diagnosis and Tracking of Non-Alcoholic Fatty Liver Disease
por: Newman, Lauren A., et al.
Publicado: (2020)

Using intestinal flora to distinguish non-alcoholic steatohepatitis from non-alcoholic fatty liver
por: Li, Chao, et al.
Publicado: (2020)

Activation and Functional Priming of Blood Neutrophils in Non-Alcoholic Fatty Liver Disease Increases in Non-Alcoholic Steatohepatitis
por: Lauszus, Johanne Sloth, et al.
Publicado: (2021)

Nonalcoholic Fatty Liver Disease and Non-Alcoholic Steatohepatitis: Current Issues and Future Perspectives in Preclinical and Clinical Research
por: Berardo, Clarissa, et al.
Publicado: (2020)

Th17 involvement in nonalcoholic fatty liver disease progression to non-alcoholic steatohepatitis
por: Chackelevicius, Carla Melisa, et al.
Publicado: (2016)

Transcriptional and Epigenetic Alterations in the Progression of Non-Alcoholic Fatty Liver Disease and Biomarkers Helping to Diagnose Non-Alcoholic Steatohepatitis
por: Zhu, Yalan, et al.
Publicado: (2023)

Myosteatosis rather than sarcopenia associates with non‐alcoholic steatohepatitis in non‐alcoholic fatty liver disease preclinical models
por: Nachit, Maxime, et al.
Publicado: (2020)

Bariatric surgery in patients with non-alcoholic fatty liver disease - from pathophysiology to clinical effects
por: Laursen, Tea L, et al.
Publicado: (2019)

Non-Alcoholic Fatty Liver Disease and Cardiovascular Comorbidities: Pathophysiological Links, Diagnosis, and Therapeutic Management
por: Jichitu, Alexandra, et al.
Publicado: (2021)

Coronary Artery Disease is More Severe in Patients with Non-Alcoholic Steatohepatitis than Fatty Liver
por: Niikura, Toshihiro, et al.
Publicado: (2020)

Identification of Autophagy-Related Genes in the Progression from Non-Alcoholic Fatty Liver to Non-Alcoholic Steatohepatitis
por: Ma, Mengyao, et al.
Publicado: (2021)

Liver Fibrogenesis in Non-Alcoholic Steatohepatitis
por: Bian, Zhaolian, et al.
Publicado: (2012)

Correlation between Fibroscan and laboratory tests in non-alcoholic fatty liver disease/non-alcoholic steatohepatitis patients for assessing liver fibrosis
por: Al Danaf, Layal, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_2pfjnhbmcurech8h8u8suukq23